{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:07:51Z","timestamp":1792555671731,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ek0109325"],"award-info":[{"award-number":["JP20ek0109325"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2042025kf0071"],"award-info":[{"award-number":["2042025kf0071"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170915"],"award-info":[{"award-number":["82170915"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31500788"],"award-info":[{"award-number":["31500788"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["S10RR026475-01"],"award-info":[{"award-number":["S10RR026475-01"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008115","name":"School of Dentistry, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008115","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR069620"],"award-info":[{"award-number":["AR069620"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR079171"],"award-info":[{"award-number":["R01AR079171"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013117","name":"International Fibrodysplasia Ossificans Progressiva Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013117","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006264","name":"RIKEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bone.2025.117565","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T03:00:43Z","timestamp":1749697243000},"page":"117565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A new BMP type 1 receptor kinase inhibitor for safe and efficient oral treatment to prevent genetically induced heterotopic ossification in mice"],"prefix":"10.1016","volume":"199","author":[{"given":"Jingwen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Sekimata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Lindenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Duford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ueharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Shirouzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Hashizume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Mishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2025.117565_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10172","article-title":"Heterotopic ossification: a comprehensive review","volume":"3","author":"Meyers","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2025.117565_bb0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.molmed.2024.08.010","article-title":"Fibrodysplasia ossificans progressiva emerges from obscurity","volume":"31","author":"Kaplan","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bone.2025.117565_bb0015","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","article-title":"The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study","volume":"24","author":"Pignolo","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.bone.2025.117565_bb0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/jbmr.2728","article-title":"The natural history of flare-ups in Fibrodysplasia Ossificans Progressiva (FOP): a comprehensive global assessment","volume":"31","author":"Pignolo","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117565_bb0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2106\/JBJS.I.00705","article-title":"Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva","volume":"92","author":"Kaplan","year":"2010","journal-title":"J. Bone Joint Surg. Am."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2025.117565_bb0030","first-page":"437","article-title":"Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons","volume":"10","author":"Pignolo","year":"2013","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.bone.2025.117565_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8090325","article-title":"Clinical aspects and current therapeutic approaches for FOP","volume":"8","author":"Kitoh","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.bone.2025.117565_bb0040","article-title":"Novel therapeutic targets for Fibrodysplasia Ossificans Progressiva: emerging strategies and future directions","volume":"15","author":"Shaikh","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bone.2025.117565_bb0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-022-01709-z","article-title":"Palovarotene: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bone.2025.117565_bb0050","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jbmr.4655","article-title":"Palovarotene for fibrodysplasia ossificans progressiva (FOP): results of a randomized, placebo-controlled, double-blind phase 2 trial","volume":"37","author":"Pignolo","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117565_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/genes14122162","article-title":"Navigating the complex landscape of Fibrodysplasia Ossificans Progressiva: from current paradigms to therapeutic Frontiers","volume":"14","author":"Anwar","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bone.2025.117565_bb0060","doi-asserted-by":"crossref","first-page":"eabp8334","DOI":"10.1126\/scitranslmed.abp8334","article-title":"An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva","volume":"16","author":"Davis","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bone.2025.117565_bb0065","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89805","article-title":"mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration","volume":"1","author":"Agarwal","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.bone.2025.117565_bb0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/humu.20868","article-title":"Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1","volume":"30","author":"Kaplan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bone.2025.117565_bb0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcdb.2015.12.013","article-title":"Granting immunity to FOP and catching heterotopic ossification in the act","volume":"49","author":"Kaplan","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bone.2025.117565_bb0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cellsig.2016.10.001","article-title":"The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response","volume":"29","author":"Hildebrand","year":"2017","journal-title":"Cell. Signal."},{"issue":"303ra137","key":"10.1016\/j.bone.2025.117565_bb0085","article-title":"ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A","volume":"7","author":"Hatsell","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bone.2025.117565_bb0090","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/nm.1888","article-title":"BMP type I receptor inhibition reduces heterotopic [corrected] ossification","volume":"14","author":"Yu","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2025.117565_bb0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cytogfr.2009.10.021","article-title":"Applications of small molecule BMP inhibitors in physiology and disease","volume":"20","author":"Hong","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bone.2025.117565_bb0100","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1248\/cpb.c18-00598","article-title":"Bis-heteroaryl pyrazoles: identification of orally bioavailable inhibitors of activin receptor-like Kinase-2 (R206H)","volume":"67","author":"Sekimata","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.bone.2025.117565_bb0105","doi-asserted-by":"crossref","first-page":"11411","DOI":"10.1021\/acsomega.9b04245","volume":"5","author":"Sato","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bone.2025.117565_bb0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-3810-0_18","article-title":"FACS fractionation and differentiation of skeletal-muscle resident multipotent Tie2+ progenitors","volume":"1460","author":"Biswas","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bone.2025.117565_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/dvg.20201","article-title":"Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2","volume":"44","author":"Fukuda","year":"2006","journal-title":"Genesis"},{"key":"10.1016\/j.bone.2025.117565_bb0120","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.ymthe.2017.01.008","article-title":"Strategic targeting of multiple BMP receptors prevents trauma-induced heterotopic ossification","volume":"25","author":"Agarwal","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bone.2025.117565_bb0125","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.4371","article-title":"Isolation and culture of cranial neural crest cells from the first branchial arch of mice","volume":"12","author":"Ueharu","year":"2022","journal-title":"Bio-protocol"},{"key":"10.1016\/j.bone.2025.117565_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz9368","article-title":"Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic \u03b2-catenin degradation","volume":"14","author":"Yang","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bone.2025.117565_bb0135","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jbmr\/zjae140","article-title":"Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial","volume":"39","author":"Keen","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117565_bb0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jbmr.3304","article-title":"Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1(R206H) mouse model of fibrodysplasia ossificans progressiva","volume":"33","author":"Convente","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117565_bb0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.bone.2025.117565_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113245","article-title":"Retinoid agonists in the targeting of heterotopic ossification","volume":"10","author":"Pignolo","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bone.2025.117565_bb0155","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/jbmr.2820","article-title":"Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) mutation","volume":"31","author":"Chakkalakal","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117565_bb0160","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40814","article-title":"Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity","volume":"7","author":"Lees-Shepard","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.bone.2025.117565_bb0165","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12874-023-02080-7","article-title":"Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva","volume":"23","author":"Pignolo","year":"2023","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.bone.2025.117565_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95042","article-title":"Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva","volume":"6","author":"Williams","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.bone.2025.117565_bb0175","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.stemcr.2018.10.007","article-title":"An mTOR signaling modulator suppressed heterotopic ossification of Fibrodysplasia Ossificans Progressiva","volume":"11","author":"Hino","year":"2018","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.bone.2025.117565_bb0180","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41591-023-02561-8","article-title":"Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"29","author":"Di Rocco","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2025.117565_bb0185","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106317","article-title":"Pathogenic ACVR1(R206H) activation by Activin A-induced receptor clustering and autophosphorylation","volume":"40","author":"Ramachandran","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.bone.2025.117565_bb0190","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54582","article-title":"Activin a forms a non-signaling complex with ACVR1 and type II Activin\/BMP receptors via its finger 2 tip loop","volume":"9","author":"Aykul","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.bone.2025.117565_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.765007","article-title":"Activin a and ALK4 identified as novel regulators of epithelial to mesenchymal transition (EMT) in human Epicardial cells","volume":"9","author":"Dronkers","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bone.2025.117565_bb0200","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbrc.2010.03.039","article-title":"Activin a induces neuronal differentiation and survival via ALK4 in a SMAD-independent manner in a subpopulation of human neuroblastomas","volume":"394","author":"Suzuki","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2025.117565_bb0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00395-017-0634-1","article-title":"The crucial role of activin a\/ALK4 pathway in the pathogenesis of Ang-II-induced atrial fibrosis and vulnerability to atrial fibrillation","volume":"112","author":"Wang","year":"2017","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.bone.2025.117565_bb0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bone.2025.117565_bb0215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bone.2025.117565_bb0220","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"10.1016\/j.bone.2025.117565_bb0225","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bone.2025.117565_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115467","article-title":"Energy metabolism: a newly emerging target of BMP signaling in bone homeostasis","volume":"138","author":"Yang","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.bone.2025.117565_bb0235","first-page":"149","article-title":"Methods for the reliable induction of heterotopic ossification in the conditional Alk2(Q207D) mouse","volume":"20","author":"Pan","year":"2020","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bone.2025.117565_bb0240","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nm.2334","article-title":"Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists","volume":"17","author":"Shimono","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2025.117565_bb0245","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/dbio.1999.9378","article-title":"Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis","volume":"213","author":"Mishina","year":"1999","journal-title":"Dev. Biol."},{"key":"10.1016\/j.bone.2025.117565_bb0250","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.stem.2007.03.002","article-title":"Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss","volume":"1","author":"Ruzankina","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bone.2025.117565_bb0255","doi-asserted-by":"crossref","first-page":"24256","DOI":"10.1038\/srep24256","article-title":"Deletion of BMP receptor type IB decreased bone mass in association with compromised osteoblastic differentiation of bone marrow mesenchymal progenitors","volume":"6","author":"Shi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2025.117565_bb0260","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1021\/acs.jmedchem.0c00395","article-title":"Targeting ALK2: an Open Science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma","volume":"63","author":"Ensan","year":"2020","journal-title":"J. Med. Chem."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225001772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225001772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:17:29Z","timestamp":1778941049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225001772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"alternative-id":["S8756328225001772"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117565","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new BMP type 1 receptor kinase inhibitor for safe and efficient oral treatment to prevent genetically induced heterotopic ossification in mice","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117565"}}